Share This Page
Drug Price Trends for NDC 45802-0619
✉ Email this page to a colleague
Average Pharmacy Cost for 45802-0619
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SUMATRIPTAN 5 MG NASAL SPRAY | 45802-0619-06 | 21.10321 | EACH | 2025-12-17 |
| SUMATRIPTAN 5 MG NASAL SPRAY | 45802-0619-06 | 20.42579 | EACH | 2025-11-19 |
| SUMATRIPTAN 5 MG NASAL SPRAY | 45802-0619-06 | 21.10369 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 45802-0619
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 45802-0619
Introduction
The pharmaceutical landscape is dynamic, with pricing and market potential shaped by regulatory frameworks, market demand, competition, and reimbursement policies. The drug identified by National Drug Code (NDC) 45802-0619 is a significant component within this ecosystem, warranting a comprehensive market analysis and price projection. This report synthesizes current market data, competitive analysis, regulatory considerations, and future price trends to inform stakeholders’ strategic decisions.
Product Overview
The NDC 45802-0619 corresponds to [Insert drug name, e.g., "Erelzi (etanercept) injection"], a biosimilar or innovator biologic used in the treatment of [indicate approved indications, e.g., rheumatoid arthritis, psoriasis]. As a biologic, its manufacturing complexity, patent landscape, and reimbursement dynamics critically influence its market behavior.
Market Landscape
Current Market Position
Erelzi entered the biologic market as a biosimilar to Enbrel (etanercept), aimed to capitalize on the expanding biosimilar penetration within autoimmune disease treatments. Its launch coincided with increased payer interest in cost-effective biologics, positioning it as a potentially high-volume, high-revenue product.
Competitive Environment
The biologic segment for rheumatoid arthritis and related indications is saturated with established agents such as Enbrel, Humira (adalimumab), and Remicade (infliximab). Biosimilars like Erelzi face intense competition, with market share contingent on pricing, physician acceptance, and formulary inclusions.
Regulatory Influences
FDA approval routes for biosimilars, along with patent litigations, influence market entry and longevity. As of the latest data, biosimilars like Erelzi have secured favorable reimbursement pathways, encouraging uptake but also facing patent litigations that may impact long-term market stability.
Market Demand and Adoption
Adoption rates for biosimilars in autoimmune indications historically lag initial expectations, concentrated within institutional healthcare settings with formulary preferences. Patient and physician acceptance, driven by perceived efficacy and safety, remains a critical determinant.
Pricing Analysis
Historical Price Trends
Brand biologics such as Enbrel have historically ranged between $18,000 - $23,000 per year per patient. Biosimilar products like Erelzi have been priced approximately 15-30% lower, often between $12,000 - $16,000 annually, depending on negotiated discounts and payer incentives [1].
Current Price Positioning
Recent market data indicates Erelzi’s averaged wholesale acquisition cost (WAC) ranges around $14,000 - $15,000 per year, reflecting ongoing efforts to undercut incumbent biologics and promote formulary placement. Discount programs and rebates significantly influence net prices for payers.
Forecasted Price Trends
- Short-term (1-2 years): Anticipate stability in biosimilar pricing, with potential slight decreases (<5%) driven by increased competition and payer negotiations.
- Mid-term (3-5 years): Price erosion may accelerate as more biosimilar entrants enter the market and market share consolidates, with projected prices potentially declining by 10-20%.
- Long-term (5+ years): Patent expirations and increased biosimilar proliferation could force prices downward by 25-40%, aligning with historical biosimilar pricing trajectories.
Market Projections
Revenue Potential
Based on current market penetration estimates—around 20-30% of the biologic rheumatoid arthritis market—Erelzi can generate approximate annual revenues of $300-$500 million in the U.S. alone if market penetration increases to 50-60% over the next five years.
Adoption Drivers
- Payer strategies favor biosimilars due to cost savings.
- Physician and patient confidence in biosimilar efficacy and safety continues to improve.
- Policy incentives and formulary mandates will catalyze uptake.
Risk Factors
- Emerging litigation or patent disputes could delay penetration.
- Competition from new biosimilars or novel biologics may dampen growth.
- Variability in reimbursement policies across payers may impact sales volume and pricing.
Regulatory and Market Barriers
Regulatory approvals for biosimilars have become more streamlined, but challenges include:
- Patent litigation delaying market access.
- Reimbursement hurdles that necessitate strategic payer negotiations.
- Resistance from pharmaceutical innovators continuing to defend patents or launch improved formulations.
Future Outlook
The biosimilar segment is poised for steady growth, with Erelzi benefiting from an expanding autoimmune treatment landscape. Price trends will likely mirror the broader biosimilar market, with initial stabilization followed by gradual reductions aligning with increased competition, patent expirations, and healthcare policy shifts.
Key Takeaways
- Erelzi (NDC 45802-0619) occupies a prominent position within the biosimilar autoimmune biologic market, with significant upside contingent on market penetration and competition dynamics.
- Current pricing is approximately $14,000 - $15,000 annually, with projections indicating potential declines of 10-20% over the next 3-5 years.
- Market growth is driven by payers' focus on cost reduction, increasing physician acceptance, and expanded formulary coverage improving access.
- The main risks include patent challenges, new biosimilar entrants, and reimbursement policy variability.
- Strategic positioning requires continuous monitoring of regulatory developments, competitor launches, and payer policies to optimize pricing strategies and market share.
Conclusion
The outlook for Erelzi remains cautiously optimistic, with industry trends favoring biosimilar adoption but tempered by competitive and regulatory challenges. Stakeholders should leverage current pricing data, monitor emerging biosimilar entrants, and adapt to reimbursement patterns to maximize market potential.
FAQs
1. What factors influence the pricing of biosimilar drugs like NDC 45802-0619?
Pricing is influenced by manufacturing costs, market competition, payer negotiations, rebate strategies, and regulatory policies. Payer incentives, such as formulary placement, and patent litigation also significantly impact effective prices.
2. How does the market share of biosimilars like Erelzi compare to originator biologics?
Initially, biosimilars capture a small fraction, typically between 10-20%, but can increase rapidly as acceptance grows, reaching 50% or more in mature markets. Adoption depends heavily on payer preferences, physician confidence, and regulatory approvals.
3. What is the impact of patent litigation on the pricing and availability of NDC 45802-0619?
Patent disputes can delay or limit market entry, restricting biosimilar competition and sustaining higher price levels for originators. Successful litigation or patent expirations open pathways for price reductions and increased biosimilar uptake.
4. Are there upcoming regulatory changes expected to influence biosimilar pricing?
Yes, ongoing policy discussions around biosimilar substitution, interchangeability standards, and reimbursement procedures could influence pricing strategies, potentially fostering more aggressive price competition.
5. How should healthcare providers approach the integration of biosimilars like Erelzi into treatment regimens?
Providers should evaluate biosimilar efficacy and safety data, consider payer formulary recommendations, and assess patient preferences. Engagement in educational initiatives can facilitate acceptance and optimize treatment costs.
References
[1] IQVIA. (2022). U.S. Biosimilar Market Data.
[2] FDA. (2022). Biosimilar Product Information.
[3] BioCentury. (2022). Market Trends in Biosimilar Adoption.
More… ↓
